 Two-year VenoValve data shows average improvements in reflux, disease manifestations and pain, of 63, 60, and 93, respectively Patients with venous ulcers who experienced dramatic ulcer healing had no venous ulcer recurrences No safety issues occurred during the one-year reporting period following the study completion IRVINE, CA ACCESSWIRE August 19, 2021 Hancock Jaffe Laboratories, Inc. NASDAQ:HJLI Hancock Jaffe or the Company, a developer of medical devices that restore cardiac and vascular health, announced that promising two-year post-VenoValve implantation data is being presented today at the Society for Vascular Surgery SVS Annual Meeting in San Diego, CA by Dr. Jorge Ulloa, who was the Principal Investigator for the Companys first-in-human VenoValve trial. Key highlights from Dr. Ulloas presentation indicate that: Reflux the backwards flow of blood decreased from an average of 1.95 to an average of .72 a 63 improvement Disease manifestations measured by rVCSS scores decreased from an average of 13.38 to an average of 5.38 a 60 improvement Pain measured by VAS scores decreased from an average of 7.25 to an average of .50 an improvement of 93 There were no safety issues or venous ulcer recurrences The data reported is for a group of eight patients that participated in the VenoValve first-in-human study and who agreed to participate in a one-year post study follow-up. 